The following mesothelioma research findings were reported in a recent issue of the Journal of Clinical Oncology. Mesothelioma researchers have reported that combining Tomudex (raltitrexed) and Platinol (cisplatin) has shown amazing results in the improved survival of patients suffering from the rare Malignant pleural mesothelioma which is caused by habitual exposure to asbestos.

According to the mesothelioma research findings reported in the journal, the combination of the two treatments dramatically improves the survival of patients compared to the use of Platinol alone.

These mesothelioma research findings emerged from a randomized phase III trial.

Patients suffering from this rare mesothelioma usually experience shortness of breath, cough, pain, fatigue and loss of appetite. This new mesothelioma research findings are all the more encouraging because this type of cancer has proved to be resistant to most therapies such as surgery, chemotherapy on its' own and even when combined with radiation.

What usually complicates matters further is the fact that usually patients are not aware of the fact that they are suffering from malignant pleural mesothelioma until the disease has already progressed to a very advanced stage where treatment with surgery or radiation is no longer a viable option.

That is why the identification of treatment that can improve survival as well as quality of life in patients, as this mesothelioma research promises, is so significant.